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ABSTRACT: Upregulation of antiapoptotic Bcl-2 proteins in
certain tumors confers cancer cell resistance to chemotherapy or
radiations. Members of the antiapoptotic Bcl-2 proteins,
including Bcl-2, Mcl-1, Bcl-xL, Bcl-w, and Bfl-1, inhibit apoptosis
by selectively binding to conserved α-helical regions, named BH3
domains, of pro-apoptotic proteins such as Bim, tBid, Bad, or
NOXA. Five antiapoptotic proteins have been identified that
interact with various selectivity with BH3 containing pro-
apoptotic counterparts. Cancer cells present various and variable
levels of these proteins, making the design of effective apoptosis
based therapeutics challenging. Recently, BH3 profiling was introduced as a method to classify cancer cells based on their ability
to resist apoptosis following exposure to selected BH3 peptides. However, these studies were based on binding affinities
measured with model BH3 peptides and Bcl-2-proteins taken from mouse sequences. While the majority of these interactions are
conserved between mice and humans, we found surprisingly that human NOXA binds to human Bfl-1 potently and covalently via
conserved Cys residues, with over 2 orders of magnitude increased affinity over hMcl-1. Our data suggest that some assumptions
of the original BH3 profiling need to be revisited and that perhaps further targeting efforts should be redirected toward Bfl-1, for
which no suitable specific inhibitors or pharmacological tools have been reported. In this regard, we also describe the initial
design and characterizations of novel covalent BH3-based agents that potently target Bfl-1. These molecules could provide a
novel platform on which to design effective Bfl-1 targeting therapeutics.
Over the past two decades, efforts in the design of effectiveapoptosis based therapeutics targeting Bcl-2 family
proteins have been based on detailed information on their
expression and preferential affinity for pro-apoptotic BH3-
containing proteins.1,2 Antiapoptotic Bcl-2 family proteins
inhibit cancer cell death by forming stable heterodimers
mediated by a conserved α-helical motif (termed BH3 domain)
present on the surface of pro-apoptotic members of the same
family. Five antiapoptotic Bcl-2 proteins, namely Bcl-2, Bcl-xL,
Bcl-w, Mcl-1 and Bfl-1, interact with various specificity with
several BH3 containing pro-apoptotic counterparts, including
Bax, Bim, Bad, tBid, and NOXA. The latter can be divided
functionally in activators, sensitizers, and effectors.3,4 The
effectors, Bax and Bak, aided by the activators Bim and Bid, are
believed to be the ultimate agents that cause MOMP
(mitochondrial outer membrane permeabilization) by forming
oligomers at the mitochondrial membrane, which result in the
release of pro-apoptogenic molecules such as SMAC and
cytochrome c.5 However, both the effectors and activators can
be sequestered by antiapoptotic Bcl-2 proteins inhibiting cell
death. Sensitizers, such as NOXA and Bad, function as cellular
sentinels that respond to cellular damage, induced by
chemotherapy, immunotherapy, or radiation in cancer cells,
and by binding to antiapoptotic Bcl-2 family proteins, displace
the bound activators and/or the effectors, resulting in
apoptosis.6
While the activators and the effectors are generally
promiscuous in binding the antiapoptotic Bcl-2 proteins, the
sensitizers have different specificity. For example, Bad binds
potently to Bcl-2, Bcl-xL, and Bcl-w, while NOXA has been
reported to preferentially bind to Mcl-1 and in minor part to
Bfl-1.7 Bcl-2 proteins expression has been highly studied in both
leukemia and lymphoma cell lines and primary cell samples,8−10
and these studies culminated in 2016 with the approval by the
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FDA of Venetoclax,11−14 a potent and selective Bcl-2 antagonist
that does not interact significantly with other antiapoptotic Bcl-
2 proteins such as Bcl-xl, Mcl-1, or Bfl-1. Accordingly, increased
Mcl-18,15 expression has been correlated with resistance to Bcl-
2 antagonists in primary tumors and cancer cell lines, and this
observation ignited intense research efforts aimed at developing
novel Mcl-1 targeting agents in the past few years.15−26 The
efficacy of these molecules as direct pro-apoptotic agents or as
sensitizers for cancer cells to chemotherapy or immunotherapy,
which act by activating cell death pathways in cancer cells,
however, largely depends on the relative levels of antiapoptotic
Bcl-2 proteins.27 Recently, BH3 profiling strategies have been
reported and widely used as a way to classify tumors and cancer
cell lines for their ability to respond to various BH3
peptides.28,29 In one implementation, cells that release
cytochrome c after exposure to Bad derived BH3 peptides
are classified as expressing Bcl-2, Bcl-xl, and/or Bcl-w, given the
affinity of Bad for these three proteins. NOXA derived BH3
Figure 1. Human NOXA interacted with human Bfl-1 covalently and potently, and with higher affinity compared to human Mcl-1. Panel A:
Structure of hBfl-1 and hNOXA complex with a close-up view of the covalent bond between the Cys 55 of hBfl-1 and the N-terminal Cys of a
hNOXA derived peptide (see sequence in Table 1) modeled on the hNOXA BH3 peptide cocrystallized with hBfl-1 (PDB ID: 3MQP). The newly
formed bond is colored in orange, while hBfl-1 is represented by light blue ribbons and hNOXA peptide by pink sticks and ribbons. Panel B: Binding
pose of a hNOXA derived peptide modeled on the hNOXA BH3 peptide cocrystallized with mMcl-1 (PDB ID: 2JM6)2. The close-up view shows
the absence of a covalent interacting Cys residue in the BH3 hydrophobic cleft of mMcl-1, here represented by gray ribbons while hNOXA peptide
by pink sticks and ribbons. Panel C: Sequence alignment of selected pro-apoptotic Bcl-2 proteins hBIK, hHRK, hBIM, hBAD, hBID, hBMF,
hNOXA, and the hBAX subfamily proteins hBAX and hBAK (upper panel). Structural alignment (lower panel) of selected antiapoptotic Bcl-2
proteins hBfl-1, hMcl-1, hBcl-2, and hBcl-xL. Bcl-2 Homology (BH) regions belonging to pro-apoptotic and antiapoptotic proteins are included in
pink and blue rectangular boxes, respectively. Interacting Cys residues present in both hBfl-1 (Cys 55) and hNOXA (Cys 25) are highlighted in
yellow, while red-colored residues indicate strictly conserved residues of pro-apoptotic proteins. Panel D: SDS-PAGE gel electrophoresis followed by
Coomassie staining of the hBfl-1 protein (10 μM) in the absence and presence of equimolar concentrations of a hNOXA derived peptide (Table 1)
at different time points (15 min, 30 min, 1h, 2h). Panel E: MALDI-TOF MS spectra of hBfl-1 collected in absence (blue) and presence (pink) of a
hNOXA derived peptide (Table 1) after 2 h incubation at RT and at a protein−ligand ratio of 1:2. Panel F: Cartoon representing the principle of the
DELFIA assays. These assays were used to quantify the ability of our test peptides to displace a biotinylated BID BH3 peptide from hBfl-1, hMcl-1,
hBcl-xL, and hBcl-2. Representative DELFIA dose−response curves relative to the hNOXA derived peptide (Table 1) against these proteins are
reported.
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peptides have been used in similar assays to detect the
expression of Mcl-1 in tumor cells, given that these peptides
bound preferentially Mcl-1 over Bfl-1 and do not interact
significantly with other antiapoptotic Bcl-2 proteins.7 While
these and several other studies clearly point at Mcl-1 as a
possible cause of resistance to Venetoclax and related
antagonists in chronic lymphocytic leukemia (CLL), other
studies suggested that Bfl-1 may have a more predominant role
in resistance to both chemotherapy and Bcl-2 antagonists.23,30
In this paper, we analyzed the interactions between NOXA,
ABT-199 (Venetoclax), and Bim with four antiapoptotic Bcl-2
proteins, namely Bcl-2, Bc-xL, Mcl-1, and Bfl-1, using
biochemical, biophysical, and cellular assays. Our studies
resulted in the surprising observation that human NOXA
derived BH3 peptides, unlike the mouse derived peptides
previously reported and commonly used for BH3 profiling,
bound with high affinity to Bfl-1 with over 2 orders of
magnitude increased affinity over Mcl-1. We also found that
this affinity is owed to a specific disulfide bridge between
NOXA and Bfl-1 that occurs only in the human proteins and
not in mice. We identified a human derived NOXA peptide that
is exquisitely selective for Bfl-1, which could be used in BH3
profiling applications and/or perhaps as a template for the
design of novel Bfl-1 antagonists. On the basis of these findings,
our studies suggest that the emphasis on Mcl-1 may need to be
revisited and that perhaps further efforts in deriving Bfl-1
specific antagonists is warranted, given that to date no valid
small molecule compounds nor pharmacological tools have
been reported. In addition, we also report on initial Bim-BH3-
based cell permeable agents that, by covalently inhibiting Bfl-1,
can serve as suitable stepping stones to derive potent Bfl-1
targeting compounds. Given the recent report by scientists at
Genentech,31 we also report a comparison between a cell-
penetrating linear and a stapled version of these covalent
peptides aimed at deriving cell active covalent Bfl-1 antagonists.
In summary, our findings should facilitate further studies
probing the role of Bfl-1 in the development of resistance in
CLL, melanomas, and other tumors and for the development of
novel apoptosis-based therapeutics.
■ RESULTS AND DISCUSSION
Human NOXA Interacted with Human Bfl-1 Cova-
lently and Potently, and with Higher Affinity Compared
to Human Mcl-1. The interaction between pro- and
antiapoptotic Bcl-2 proteins has been proven in several
instances to be mediated by a conserved α-helical BH3 peptide
on the surface of pro-apoptotic proteins that bound with
various affinities and specificities to a BH3-binding groove
present on the surface of antiapoptotic Bcl-2 proteins. Hence,
biophysical studies on several BH3 peptides in complex with
various antiapoptotic Bcl-2 proteins have been reported over
the past two decades.32
The X-ray structure of human Bfl-1 in complex with a BH3
peptide from NOXA (Figure 1A) was recently deposited in the
protein data bank (PDB ID 3MQP). While the general
positioning of the peptide into the BH3 binding groove of Bfl-1
largely resembled that of the previously reported complexes
between other BH3 peptides and other antiapoptotic Bcl-2
family proteins (for example, mNOXA B/mMcl-1 complex in
Figure 1B; PDB ID 2JM633), we noticed that hBfl-1 presented a
unique and peculiar structural feature. The conserved residue
Cys 25 in hNOXA (Figure 1A,C) was precisely juxtaposed to
the conserved residue Cys 55 in human Bfl-1 (Figure 1A,C), to
possibly form a disulfide bond. Accordingly, we found that a
hNOXA BH3 peptide (Table 1) and a human Bfl-1
recombinant construct that lacked the C-terminal trans-
membrane domain (hBfl-1ΔTm(1−149)) formed a covalent
complex, as we could observe by SDS gel electrophoresis
(Figure 1D). Moreover, further confirmation of covalent
modification of hBfl-1 was obtained using MALDI TOF mass
spectrometry, which demonstrated the expected mass increase
when hNOXA was incubated with hBfl-1. Specifically, we
observed the following masses: hBfl1ΔTM(1−149) = 19673.8
Da; hNOXA = 2463.0 Da; complex hBfl-1/hNOXA = 22134.4
Da, which is nearly identical (well within the accuracy of the
method) to the exact expected theoretical mass of the covalent
adduct, 22134.8 Da (Figure 1E).
Over the past several years, most laboratories have relayed on
a fluorescence polarization assay to quantify the ability of Bcl-2
antagonists to displace FITC-labeled BH3 peptides. While this
assay has been used with some success, we found that it is
prone to producing false positives, owed to the indirect nature
of the readout and the relatively narrow assay window. In fact,
the assay relied on indirect measurements of the overall
rotational diffusion times of the peptide in the free and bound
state. Compounds with low solubility may have an effect on the
solubility of the peptide, usually present in the assay well at
relatively low (nanomolar) concentrations relative to test
agents that could result in false positives, or artificially low or
otherwise inaccurate inhibition constants. For these reasons, we
opted to derive a more robust assay, as we recently reported.34
Hence, we developed a panel of assays based on the DELFIA
(Dissociation Enhanced Lanthanide Fluorescence Immuno-
assay) platform34 for hBcl-2ΔTm, hMcl-1ΔTm, hBcl-xLΔTm,
Table 1. NOXA Derived Peptide Sequences and Relative IC50 Values in a DELFIA Assay against the Bcl-2 Family Proteins hBfl-
1, hMcl-1, hBcl-xL, and hBcl-2a
DELFIA IC50 (nM)
compd ID aa sequence hBfl-1 hMcl-1 hBcl-xL hBcl-2
hNOXA Ac-CATQLRRFGDKLNFRQKLLN-NH2 7.5 ± 2 228 ± 1 >1 μM >1 μM
homo_hNOXA Ac-hCATQLRRFGDKLNFRQKLLN-NH2 83 ± 11 266 ± 31 >1 μM >1 μM
λ_hNOXA Ac-λATQLRRFGDKLNFRQKLLN-NH2 287 ± 69 233 ± 25 >1 μM >1 μM
hNOXAs Ac-CATQLRRFGDKLN-NH2 15 ± 2 >1 μM >1 μM >1 μM
NOXA A Ac-AELPPEFAAQLRKIGDKVYC-NH2 >1 μM 450 ± 1 >1 μM >1 μM
NOXA B Ac-PADLKDECAQLRRIGDKVNL-NH2 431 ± 35 479 ± 28 >1 μM >1 μM
C1A_hNOXAs Ac-AATQLRRFGDKLN-NH2 >1 μM >1 μM n.t. n.t.
cyc_hNOXA Ac-CATQLRRFGDKLNFRQKLLNLISKLFC-NH2 86 ± 13 344 ± 41 n.t. n.t.
ahC = homocysteine; λ = Dap-2-chloroacetamide; C1−C27 in cyc-NOXA = disulfide bridge. n.t.: not tested. Values are the results of multiple
measurements run in duplicates and represent the mean ± SE.
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and hBfl-1ΔTm (Figure 1F). In these assays, a biotinylated Bid
BH3 peptide was captured on DELFIA streptavidin coated
plates (see Methods), while histidine tagged recombinant
proteins were conjugated with a highly fluorescent Eu-tagged
anti-His antibody (PerkinElmer, see Methods). After washing
steps, the displacement of the immuno-reaction complex from
the assay well by a test molecule was detected by a decrease in
fluorescence signal (Figure 1F).34
Using this robust biochemical assay, we tested the ability of
hNOXA BH3 peptide (Table 1) to displace the binding of Bid-
BH3 from selected antiapoptotic proteins. Not surprisingly,
hNOXA did not show any appreciable affinity for both Bcl-2
and Bcl-xL, as previously reported,7 while it displayed a greater
affinity for both hMcl-1 and hBfl-1. Mouse derived NOXA A
peptide, commonly used to detect Mcl-1 in BH3 profil-
ing,29,35−39 indeed interacted more potently, albeit with triple
digit nanomolar affinity with hMcl-1 compared to hBfl-1 (Table
1). NOXA B on the contrary had similar relatively weak
affinities for both human proteins (Table 1). This affinity trend
followed what was reported previously using these mouse-
derived NOXA peptides tested against mouse Mcl-1 and mouse
Bfl-1. These previous studies originated the common knowl-
edge that Mcl-1 has a greater affinity for NOXA than Bfl-
1.7,29,35−39 However, contrary to these observations, here we
found that human NOXA displayed a dramatically greater
affinity for human Bfl-1 than human Mcl-1. The increased
affinity of human NOXA for human Bfl-1 versus human Mcl-1
could be attributable to a covalent interaction between hBfl-1
and hNOXA. Such interaction was structurally unique and not
present in other BH3 peptides (including mouse derived
Figure 2. Characterization of covalent hBIM derived peptides. Panel A: Structure of hBfl-1 in complex with hBIM (PDB ID: 2VM6). The close-up
view shows the presence of a Trp residue in hBIM (Trp 147) that corresponds to Cys 25 in hNOXA (see Figure 1). hBfl-1 is represented by light-
blue ribbons, while hBIM peptide is represented by purple sticks and ribbons. Panel B: Structure of the complex between hBfl-1 and a covalent hBIM
derived peptide named 130E7 (Table 1) with a close-up view of the covalent bond between the Cys 55 of hBfl-1 and the Dap-2-chloroacetamide in
130E7 modeled on the hBIM BH3 peptide from the PDB ID 2VM6. The newly formed bond is colored in orange, while hBfl-1 is represented by
light blue ribbons and 130E7 is depicted as green sticks and ribbons. Panel C: Dose−response DELFIA curves for the displacement of a BID peptide
from the Bcl-2 family proteins hBfl-1, hMcl-1, hBcl-xL, and hBcl-2 by compounds 130E7, 130E8 (hBIM), and ABT-199. The arrows emphasize
differences in affinities against each of the tested proteins between 130E7, ABT-199, and 130E8. The covalent agent 130E7 showed an increase in
affinity only against Bfl-1, owed to the covalent interaction with Cys 55, while reduced affinities are observed between this agent and other Bcl-2
proteins lacking such residues in the BH3 binding groove. Panel D: SDS-PAGE gel electrophoresis followed by Coomassie staining of the hBfl-1
protein (10 μM) in absence and presence of equimolar concentrations of 130E7 at different time points (15 min, 30 min, 1 h, 2 h). Panel E: MALDI-
TOF MS spectra of hBfl1 collected in the absence (blue) and presence (green) of 130E7 after 2 h incubation at RT and at a protein−ligand ratio of
1:2.
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NOXA A peptide, for example) or in other antiapoptotic Bcl-2
proteins (Figure 1C). The mouse derived NOXA B peptide did
contain a Cys residue, but this did not appear to be at the
proper position in the BH3 sequence for covalent interaction
(Table 1).
While submitting this manuscript, Huhn et al. reported on
covalent stapled (but not the corresponding linear) NOXA and
BIM peptides.40 However, we want to emphasize that a lack of
quantitative information in these recent studies precluded the
authors from making these critical observations on the relative
affinities of hNOXA for hBfl-1 and hMcl-1. Because the binding
of hNOXA for hBfl-1 was likely driven by the disulfide bridge
formation, we derived a minimal peptide region (hNOXAs,
Table 1) that retained a low nanomolar affinity for hBfl-1 (IC50
= 15 nM) while no displacement was observed for this agent
when tested against other antiapoptotic Bcl-2 family proteins
including hMcl-1 (Table 1) up to 1 μM. In agreement,
mutating the Cys residue in hNOXA peptide resulted in an
inactive molecule (Table 1, Supporting Information Figure S1),
further demonstrating the dependence of the disulfide bridge
for the interaction between hBfl-1 and hNOXA. The striking
differences between mouse NOXA, possessing two BH3
domains (namely NOXA A and NOXA B), and human
NOXA, having only one BH3 domain whose activity seemed
dependent on a specific disulfide bridge formation with hBfl-1,
may be due to different activation and regulation mechanisms
of these proteins. While detailed structural studies on mouse or
human NOXA have remained elusive, a recent report suggested
that human NOXA was regulated by a specific phosphorylation
event at Ser 13.41 A current hypothesis based on modeling
studies suggested the presence of a phosphorylated, cytosolic,
inactive version of NOXA that could bring the BH3 helix and
the transmembrane helix together to form an α-hairpin.41 On
the basis of such a model, we hypothesized that this
conformation may be stabilized/regulated by an intramolecular
disulfide bridge between Cys 25 in the BH3 domain and Cys 51
in the TM helix of hNOXA, also unique to this protein among
the Bcl-2 family proteins. This structural motif was previously
hypothesized, and it is present in nature in other proteins.42 To
preliminarily test this hypothesis, we synthesized a truncated
cyclic NOXA peptide (cyc_hNOXA, Table 1), constituted by
the BH3 helix from Cys 25 and the TM helix up to Cys 51 that
are disulfide bridged. This “closed” conformation of the protein
resulted in a significantly reduced affinity for hBfl-1 (IC50 =
85.8 nM, Table 1) when tested side by side with the linear
version. While still speculative, these preliminary studies may
suggest that, in addition to phosphorylation of Ser13, a possible
redox mechanism of regulation of hNOXA would involve the
reduction of an intramolecular disulfide bridge that would
expose the TM domain for translocation to the mitochondrial
membrane. These observations would also explain the
activation of NOXA (but not other pro-apoptotic factors) by
UV radiation,43 given that UV may catalyze the opening of the
disulfide bridge. In tumors cells, dysfunctional mitochondria
can cause a shift from oxidative phosphorylation to active
glycolysis that in turn increases ROS (reactive oxygen species)
generation. Hence, under our hypotheses and observations,
such altered redox potential in cancer cells could be a target for
both hNOXA activation and/or hNOXA/hBfl-1 interactions.
In conclusion, our observations that hNOXA had greater
affinity for hBfl-1 may have tremendous implications on
defining the role of hBfl-1 in cancer cell resistance that thus
far have been overlooked, despite several reports.15,44,45
Moreover, we have identified that hNOXA derived peptides
can serve as hBfl-1 potent BH3 agents that can be generally
used for profiling, perhaps complementing the recent work by
Butterworth reporting an elegant application of molecules in
BH3 profiling,46 or to generate possibly cell permeable
therapeutics such as stapled peptides40 or using other cell
permeabilization techniques. Finally, albeit speculative, our
findings provide a structural framework for the possible
regulation and activation of hNOXA via intra- and
intermolecular disulfide bond formations that will require
further investigations.
Introducing a Mild Michael Acceptor in Bim BH3
Peptide Produced a Potent, Covalent hBfl-1 Antagonist.
Analysis of the crystal structure of hBfl-1 in complex with a
hNOXA peptide revealed that the distance between the sulfur
atoms of hNOXA Cys 25 and hBfl-1 Cys 55 was approximately
3.7 Å (Figure 1A), although a second more distant rotamer for
the side chain of Cys 55 in Bfl-1 was also deposited in the PDB
ID 3MQP. Because of the presence of this second
conformation in which Cys 55 is more distant from Cys 25
in hNOXA, we synthesized and tested two additional hNOXA
derived BH3 peptides (Table 1) in which the conserved Cys 25
was replaced by either a homoCys (hence one carbon longer)
or a mild Michael acceptor (Dap-2-chloroacetamide, hence two
atoms longer than the Cys; Table 1). By using the DELFIA
displacement assay, hNOXA remained the most active against
hBfl-1 (Table 1), although all peptides were able to covalently
Table 2. BIM Derived Peptide Sequences and Relative IC50 Values in a DELFIA Assay against the Bcl-2 Family Proteins hBfl-1,
hMcl-1, hBcl-xL, and hBcl-2a
aλ = Dap-2-chloroacetamide, Xi and Xi+4 = (S)-2-(4′-pentenyl)alanine
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interact with hBfl-1 by SDS gel electrophoresis (Supporting
Information Figure S2).
On the basis of these observations, we further analyzed the
structure of the complex between BIM-BH3 and hBfl-1 (PDB
ID 2VM6; Figure 2A).47 We chose the BIM residue Trp147 as
a possible target for the introduction of a mild Michael acceptor
to react covalently with hBfl-1, thus mimicking what we
observed with hNOXA. The distance between the γ-carbon of
the side chain of Trp147 and the sulfur atom of hBfl-1 Cys 55 is
3.8 Å from the X-ray structure (PDB ID 2VM6;47 Figure 2A)
and therefore represented an ideal place for the placement of a
mild Michael acceptor. Our considerations in designing
covalent peptides followed the general strategies as we recently
reported while targeting the ubiquitin ligase SIAH interactions
with a peptide derived by the protein Sip.48 On the basis of this
experience, we introduced a Dap-2-chloroacetamide in lieu of
Trp 147 in a BIM BH3 peptide (Table 2). The resulting agent,
130E7 (Table 2), was tested against the four antiapoptotic Bcl-
Figure 3. Selectivity profiling and in vitro evaluation of two covalent cell penetrating peptides. Panel A: Cartoon representation of 130G4, derived by
linking the N-terminus of 130E7 to a cell penetrating sequence constituted by five PRR repeats (Table 1). Panel B: Cartoon representation of
130D11, a hydrocarbon stapled derivative of 130E7 (Table 1). In the sequences of the peptides reported in panels A and B, we used the same
abbreviations as in Table 1: λ = Dap-2-chloroacetamide, Xi and Xi+4 = (S)-2-(4′-pentenyl)alanine. Panel C: Dose−response curves for the
displacement of a BID peptide from the Bcl-2 family proteins hBfl-1, hMcl-1, hBcl-xL, and hBcl-2 by compounds 130G4 and 130D11 in DELFIA
assays. Panels D and E: NUPAGE gel electrophoresis followed by Coomassie staining of 130G4 and 130D11 against selected Bcl-2 family proteins
(hBfl-1, hBcl-xL, hBcl-2, hMcl-1) after 2 h incubation at RT and at a protein−ligand ratio of 1:2. The noncovalent peptide 130E8 (Table 1) was used
as negative control. Panel F: Superimposition of the amide region (6−9 ppm) in the 1D 1H NMR spectra of 100 μM 130D11 (blue), 130G4 (red),
and 130E7 (black) to address compounds’ solubility. The spectra were collected in PBS buffer at pH = 7.4 containing 10% D2O + 1% d6-DMSO. 3-
(Trimethylsilyl) propionic-2,2,3,3-d4 acid (TMSP) at 11.1 μM has been used as an internal reference (0.0 ppm). Panel G: Isothermal titration
calorimetry experiments of 130G4, 130D11, and 130E7 against hBfl-1. Kd values in the low nanomolar range were observed for 130G4 and 130E7
(Kd = 23.0 nM and 2.6 nM, respectively) while, likely due to its limited solubility, no significant binding was observed for 130D11 under our
experimental conditions. Similar data were obtained against other Bcl-2 family proteins (Supporting Information Table S2).
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2 proteins using the DELFIA assays (Figure 2C, Table 2), side
by side with the wild type BIM BH3 corresponding peptide
(Table 1) and the Bcl-2 selective antagonist ABT-199
(Venetoclax;14 Table 2). The BIM BH3 peptide was cross-
reactive with all four Bcl-2 proteins as previously reported, with
IC50’s in the nanomolar range (Figure 2C, Table 2). However,
the introduction of the Dap-2-chloroacetamide in the peptide
resulted in an agent (130E7) that was more potent against hBfl-
1 compared to the other Bcl-2 proteins tested, again owed to
the covalent nature of these interactions. In comparison, ABT-
199 resulted as the most potent against Bcl-2 and inactive
against Bcl-xL, Mcl-1, and Bfl-1 (Table 2), again in agreement
with what was recently reported for this agent.14 To further
characterize the binding mode of 130E7 for hBfl-1, we tested its
ability to form a covalent adduct in vitro (Figure 2D,E). The
molecule interacted with hBfl-1 covalently as demonstrated by
Figure 4. Cellular validation of compound 130G4. Panel A: Western-blot analysis of HEK293 cells transfected with N-HA-tagged hBfl-1 and treated
for 6 h with increasing concentrations (10, 20, 30, 50 μM) of 130G4. Cells treated with DMSO only were loaded as negative controls. Samples were
probed with an anti-HA antibody (see Methods). Molecular weight shifts corresponding to the covalent adducts of hBfl-1 are indicated. Panel B:
Viability dose−response curve of human malignant melanoma SKMEL-5 cells exposed for 24 h to different concentrations (from 0.4 to 100 μM) of
the test compound 130G4. Antiproliferative activity was assessed using the ATPlite assay from PerkinElmer and normalized to control cells which
were treated with the vehicle, DMSO. The reported IC50 value was calculated by Prism5 (GraphPad). Panel C: Synergistic assay on Raji cell line
derived cells incubated with the hBfl-1 inhibitor 130G4 alone (1, 5, 10, 30 μM) or in combination with different concentrations of Fludarabine (F-
ara-A, 1, 3, 10 μM) or Etoposide (10, 30, 90 μM) for 48 h at 37 °C in a CO2 incubator. The in vitro cytotoxicity was measured using PI/DiOC6
followed by flow cytometry data analysis, and the data were reported as % SIA (specific induced apoptosis, see Methods). Panel D: Evaluation of a
synergistic effect of 130G4 with etoposide and fludarabine (F-ara-A) in CLL cells and CLL cells cocultured with stromal cell support. In the washout
experiment, CLL cells alone or cocultured with stroma-NK-tert cells were incubated with the Bfl-1 inhibitor 130G4 alone or in combination with
different concentrations of fludarabine (F-ara-A) or etoposide for 48 h at 37 °C in CO2 incubator. The in vitro cytotoxicity was measured in all the
samples after 48 h using CD19/CD5/DioC6 staining followed by flow cytometry data analysis, and the data were presented as % SIA (specific
induced apoptosis). The two graphs in the panel represent data collected from two different CLL patients.
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SDS gel electrophoresis (Figure 2D). In addition, to further
confirm the covalent modification of hBfl-1, we used MALDI
TOF mass spectrometry, which demonstrated the expected
mass increase when 130E7 was incubated with hBfl-1 (Figure
2E). Specifically, we observed the following masses:
hBfl1ΔTM(1−149) = 19673.8 Da; 130E7 = 2545.5 Da;
complex hBfl-1/130E7 = 22182.6 Da (theoretical expected
mass for the covalent adduct is 22183.3 Da). Therefore, these
data identified that 130E7 is a potent, covalent hBfl-1
antagonist.
Cell Permeable Covalent Bim-BH3 Mimetics Target-
ing Bfl-1: Biochemical and Biophysical Validation. To
study the effect of hBfl-1 inhibition in cells, cell penetrating
versions of 130E7 were designed and tested. Two parallel
strategies were adopted either using an N-terminal cell
penetrating sequence (130G4, Figure 3A) or by synthesizing
a hydrocarbon stapled version of the agent (130D11, Figure
3B), similar to what was reported for the linear BIM BH3
peptide.49−52 A similar covalent stapled peptide was reported
while this manuscript was submitted,40 using an acrylamide
instead of a Dap-2-chloroacetamide as we report here.
However, characterization of such an agent with respect to
affinity and selectivity for Bcl-2 proteins has not been reported
in detail, and the manuscript relied only on SDS page to prove
the covalent interaction.40 Here, we carefully tested each
molecule in DELFIA displacement assays against the selected
antiapoptotic Bcl-2 proteins, in addition to SDS gel electro-
phoresis, MALDI TOF spectrometry, and isothermal titration
calorimetry. Introducing a cell penetrating sequence at the N-
terminus of 130E7 (resulting in agent 130G4; Figure 3A, Table
2), or introducing a hydrocarbon staple in 130E7 (resulting in
the stapled peptide 130D11; Figure 3B, Table 2), did not
significantly alter their respective binding affinities for hBfl-1,
likely driven by the covalent interactions (Table 2). However,
the binding of the stapled 130D11 to other Bcl-2 proteins got
somewhat reduced, in agreement with recent observations
about the stapled version of BH3 peptides31 (Figure 3C, Table
2). Surprisingly, these comparative data between linear and
stapled versions of these covalent agents have not been
reported by Huhn et al.40 The selectivity of the covalent
interaction against hBfl-1 for both agents was further probed by
SDS gel electrophoresis by incubating each agent with hBfl-1,
hMcl-1, hBcl-2, or hBcl-xL as shown in Figure 3D for 130G4
and in Figure 3E for 130D11. A new band for the adduct was
observed only when hBfl-1, and not the other proteins, was
exposed to the covalent agents (Figure 3E,F). The new bands
appeared at approximately the expected molecular weights:
expected MW for hBfl-1/130G4 adduct, 24265 Da; expected
MW for hBfl-1/130D11 adduct, 22183 Da (Figure 3 E,F). In
addition, and again in agreement with previous recent studies,31
introduction of the hydrocarbon staple significantly reduced the
solubility of the resulted agent, 130D11, as evident by 1D 1H
NMR (Figure 3F). To further characterize the direct
dissociation constants and the thermodynamics of binding of
these agents to hBfl-1, we tested them using isothermal titration
calorimetry (ITC; Figure 3G), resulting in Kd values in the low
nanomolar range against hBfl-1 (2.6 and 23.0 nM, for 130E7
and 130G4, respectively; Figure 3G and Table S2). However,
likely due to its limited solubility, the binding of the
hydrocarbon stapled version (130D11) to hBfl-1 was not
detected under our experimental conditions (Figure 3G). In
addition, the affinity for Bcl-2 and Bcl-xl also was significantly
compromised in the stapled peptide, compared to the linear
peptide, similar to what was recently reported.31 As mentioned,
covalent stapled versions of NOXA and BIM derived peptides
were reported while this manuscript was submitted; however,
and surprisingly, no detailed quantitative information on the
relative binding affinities between linear and stapled agents nor
between covalent and noncovalent agents was reported.40
Bfl-1 Inhibition Reverted Resistance to Apoptosis in
Cell Lines and Primary CLL Cells. To further assess the
ability of our hBfl-1 covalent antagonists to penetrate live cells,
we tested them against HEK293 cells that were transfected with
HA-tagged-wt-hBfl-1 (Sino biologicals). In this assay, cell
penetration by the agents and formation of the covalent adduct
was visible by simple Western blot analysis owed to the
increased molecular weight of the covalent complex. 130G4 was
able to penetrate the cell membrane and form a covalent adduct
with hBfl-1 in a dose dependent manner after exposure of
transfected cells with the agents for 6 h, as suggested by the
new band that has approximately an increase of 5 kDa in MW
(Figure 4A). On the contrary, reliable cell permeability data
with the stapled peptide were difficult to obtain due to the
limited solubility of the agent. Hence, for further cellular
studies, we preferred 130G4 to the less soluble hydrocarbon
stapled 130D11. Indeed, a similarly derived covalent BIM staple
peptide recently reported was tested only at relatively high
concentrations (40 μM) to detect cellular activity.40 In
agreement, when tested against a melanoma cell line that
expressed higher levels of both NOXA and Bfl-1 SKMEL-5,9,53
we observed that while 130G4 was active in the low micromolar
range, 130D11 was inactive up to 10 μM. Indeed, cell activities
for a similar stapled covalent peptide recently reported were
obtained only at 40 μM.40 Hence, we subsequently tested
130G4 against the lymphoma cell line Raji, a line that expresses
Bfl-1,53 and measured the specific induced apoptosis (SIA) by
the agent when used alone or in combination with fludarabine
or etoposide at different concentrations (Figure 4C). In these
experiments, 130G4 had single agent activity with EC50 values
<5 μM (Figure 4C). However, testing etoposide or fludarabine
in the presence of 5 μM of 130G4 dramatically sensitized this
cell line to the agents (Figure 4C). Similarly, we preliminarily
tested the agent against primary cells isolated from patients
affected by chronic lymphocytic leukemia (CLL) that are
resistant to fludarabine or etoposide (Figure 4D). These
experiments were conducted against the CLL cells alone or
cocultured with stroma-NK-term cells to best reproduce the
tumor environment. In both experiments 130G4 had similar
single agent activity (EC50 < 5 μM), while both fludarabine and
etoposide had limited activity. However, at the least, an additive
effect was observed when the agents were used in combination,
suggesting that 130G4 or agents with similar activity against
Bfl-1 could be used in fludarabine resistant patients.
Previous cellular and genetic studies implicated Bfl-1 as a
critical Bcl-2 family protein responsible for the resistance to
both chemotherapy and Bcl-2 antagonists treatment in CLL
and in melanomas. However, misleading binding data using
mouse NOXA derived BH3 peptides (NOXA A and NOXA B,
Table 1), which bound more potently to Mcl-1, out-shadowed
the role of Bfl-1 in cancer cells. Our studies also revealed a
possible mechanism of interaction between hNOXA and hBfl-1
that we hypothesized being regulated by the formation of an
intermolecular disulfide bridge with a Cys in the TM domain of
the protein, in a cytosolic, inactive state of the protein. These
observations, if confirmed, could have far reaching ramifications
in deciphering a possible mechanism of redox-regulation of
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apoptosis in cells and may stimulate the design of novel
covalent inhibitors that exploit the conserved Cys 55 in hBfl-1.
To this end, our studies with our preliminarily derived cell-
permeable covalent agent provide the necessary proof-of-
concept data and represent a valuable stepping stone for the
design of more drug like agents.
■ METHODS
Protein Expression and Purification. hBfl-1 Protein Expression.
A modified pET21a vector encoding a human Bfl-1 fragment (residues
1−149) and an N-terminal His tag was used for these studies.
Transformed Rosetta-gami (DE3) competent cells (Novagen) were
transferred to Luria broth (LB) supplemented with the appropriate
antibiotic and allowed to grow at 37 °C under shaking conditions.
When the optical density reached 0.7, the culture was induced with 0.1
mM IPTG (isopropyl 1-thio-D-galactopyranoside) and the growing
cells were left shaking overnight at 15 °C. Bacteria were collected and
lysed at 4 °C. The overexpressed protein was purified using Ni2+
affinity chromatography with a linear gradient of imidazole. The eluted
fractions were dialyzed against a buffer containing 50 mM phosphate
and 150 mM NaCl, at pH = 6.5. Typical yields were 0.8 g/L. The final
prote in sequence was MHHHHHHSSGVDLGTENLYF-
QSMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQ-
NVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKE-
FEDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEI-
SYFVAEFIMNNTGEWIRQNGGWENGFVKKFE. Similarly, hBcl-xL
samples were prepared and purified as described previously.54 Briefly,
E. coli strain BL21 was transformed with the pET-21b plasmid
(Novagen) carrying the gene coding for Bcl-xL ΔTM (Bcl-xL deletion
mutant lacking the transmembrane domain). Bacteria were grown at
37 °C, and induction of protein expression was carried out when the
OD600 reached 0.6 with 1 mM IPTG for 4 h at 37 °C. Following cell
harvest and lysis by sonication, hBcl-xL was purified using a Ni-affinity
column (Amersham). The eluate was dialyzed against 40 mM
phosphate buffer (pH = 7.5) and 150 mM NaCl. Likewise, the
hMcl-1 (172−323) gene was inserted into a pET15b vector for
expression in E. coli. Bacteria cultures were induced when OD600
reached 0.6 with 1 mM IPTG and left shaking overnight at 20 °C.
Similarly to hBfl-1 and hBcl-Xl, hMcl-1 protein was purified using Ni2+
affinity chromatography with a linear gradient of imidazole.
Recombinant hBcl-2 protein was purchased from Sino Biologicals.
Agents and Peptides. Linear peptides were synthesized on a
Liberty Blue microwave peptide synthesizer (CEM Corporation, NC)
and a PS3 automated peptide synthesizer using Fmoc protocols.
Stapled and covalent peptides reported in Tables 1 and 2 were
synthesized by InnoPep (San Diego, CA) following standard solid
phase peptide synthetic procedures. Fmoc-Dap-2-chloroacetamide−
OH was prepared and incorporated as a building block at the N-
terminus of selected peptides in solid phase conditions.
Mass Spectrometry Analysis. Molecular weight analysis was
done using an Autoflex II MALDI TOF/TOF (Bruker Daltonics).
hBfl-1 was incubated in the absence and in the presence of hNOXA
and 130E7 in a 1:2 ratio for 2 h. For mass spectroscopy analysis, equal
volumes (2 μL) of each sample dissolved in the reaction buffer (16
mM phosphate, 50 mM NaCl, pH = 6.5) and MALDI Matrix solution
(sinapic acid; 20 mg mL−1 in 50% acetonitrile -0.1% trifluoroacetic
acid solution) were cocrystallized on the MALDI target plate and
allowed to air-dry for 10 min. Mass spectra were acquired and
processed with FlexAnalysis 2.4. The control protein molecular weight
spectra as well as the protein and peptide conjugated spectra are
shown. The protein mass shift correlating to peptide molecular weight
was observed in a conjugated sample. The data were further processed
using the FlexAnalysis peak picking method. With our current
instrumentation and these experimental conditions, we expect on
average a variation in the observed molecular mass of about ±50 Da,
depending on the presence of slightly different ionization states of side
chains, the presence of different numbers of nature of counterions, etc.
DELFIA (Dissociation Enhanced Lanthanide Fluorescence
Immunoassay). One hundred microliters of a 600 ng/mL solution of
biotin-BID (Biotin-lc-EDIIRNIARHLAQVGDSMDR-NH2, where lc
indicates a hydrocarbon chain of six methylene groups, aminohexanoic
acid) was added to each well of 96-well streptavidin-coated plates
(PerkinElmer). After 2 h of incubation and elimination by three
washing steps of the unbound biotin-BID peptide, 11 μL of a
preincubated solution of the protein and a serial dilution of the test
peptide were added to the assay plate, followed by the addition of 89
μL of a 1.56 nM solution of Eu−N1-labeled anti-6xHis Antibody
(PerkinElmer). After 1 h of incubation at RT to allow the
immunoreaction to complete, a second washing step allowed removal
of the unbound protein in complex with Eu antibodies if displaced by a
test compound. Subsequently, 200 μL of enhancement solution
(PerkinElmer) was added to each well and fluorescence measured after
10 min of incubation (excitation wavelength, 340 nm; emission
wavelength, 615 nm). The protein final concentrations, determined by
titrations, were 15 nM for hBfl-1, 16 nM for hMcl-1, 7 nM for hBcl-2,
and 8.5 nM for hBcl-xL, while the antibody final concentration was
22.2 ng/well when compounds were tested against hBfl-1, hMcl-1, and
hBcl-xL and 14.8 ng/well in the presence of hBcl-2. Each well received
a final DMSO concentration equal to 1%. Protein, peptide, and
antibody solutions were prepared in DELFIA assay buffer
(PerkinElmer). Counts were normalized to control wells, which
were treated with the vehicle, DMSO, and reported as % of inhibition.
The reported IC50 values were calculated by Prism5 (GraphPad).
Gel Electrophoresis. Synthetic peptides were incubated for 2 h
and at equimolar concentration (10 μM) with human Bcl-2 family
proteins (hBfl-1, hMcl-1, hBcl-2, hBcl-xL). Note that the paper from
Huhn et al. used 40 μM protein and 120 μM peptides.40 Samples were
subjected to gel electrophoresis with SDS-PAGE gel followed by
treatment with Coomassie dye as a staining protocol. For protein band
detection, the NuPAGE 12% bis-tris mini gels (Life Technologies)
were stained with SymplyBlue SafeStain (Life Technologies) according
to the manufacture’s protocol.
NMR Spectroscopy. NMR spectra were acquired on a 600 MHz
Bruker Avance spectrometer equipped with a TCI cryoprobe. All
NMR data were processed and analyzed using TOPSPIN2.1 (Bruker
Biospin, Billerica, MA, USA) and SPARKY3.1 (University of
California, San Francisco, CA, USA). Solubility of test compounds
was evaluated at 100 μM and in the following buffer conditions: PBS
at a pH = 7.4 containing 10% D2O + 1% d6-DMSO. 3-(Trimethylsilyl)
propionic-2,2,3,3-d4 acid (TMSP) at 11.1 μM was used as an internal
reference (0.0 ppm).
Isothermal Titration Calorimetry and Molecular Modeling.
Isothermal titration calorimetry was performed on a VP-ITC
calorimeter from Microcal (Northampton, MA, USA). When
indicated, measurements were performed in a reverse fashion (i.e.,
the protein was titrated into the compound solution). All titrations
were performed at 25 °C in PBS buffer supplemented with 10%
DMSO. Experimental data were analyzed using Microcal Origin
software provided by the ITC manufacturer (Microcal). Modeling
studies and figures were prepared using Chimera (http://www.cgl.ucsf.
edu/chimera).
Cell Based Assays. Antiproliferative Activity of SKMEL-5 Cells.
Human malignant melanoma SKMEL-5 cells were obtained from the
American Type Culture Collection (ATCC HTB-70, Manassas, VA,
USA) and were maintained in 5% CO2 at 37 °C and cultured in
Eagle’s Minimum Essential Medium (EMEM; Cellgro) plus
GlutaMAX supplemented with 10% fetal bovine serum (FBS;
Omega Scientific) and 1% penicillin/streptomycin (Omega Scientific).
Approximately 30 000 cells were seeded into individual wells of a
96-well tissue culture plate and incubated for 24 h. Cells were
replenished with fresh medium (0.1 mL/well; 5% FBS, no antibiotics)
and exposed to triplicates of different concentration solutions (from
0.4 to 100 μM) of test compounds. The analyzed inhibitors were
dissolved in DMSO, reaching a final DMSO concentration of 1%. After
incubation for 24 h at 37 °C and 5% CO2, cell viability was assessed
using ATPlite assay from PerkinElmer (Waltham, MA). Viability was
normalized to control cells which were treated with the vehicle,
DMSO. The reported IC50 values were calculated by Prism5
(GraphPad).
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Western Blot. Twenty-four hours before the transfection,
HEK293T was plated into a six-well plate at a seeding density of
500 000 cells per well. At 90% confluence, cells were transfected with
N-HA-tagged Bfl1 (Bcl-2-related protein A1, full length; organism,
Homo sapiens; catalog number, HG10562-NY, Sino Biological Inc.), by
using the jetPRIME transfection reagent (Polyplus). After 16 h,
different concentrations of Bfl1 inhibitors were added to the cells at a
final DMSO concentration of 1% and incubated for 6 h. Cells were
then washed with cold PBS and lysed with lysis buffer (50 mM Tris-
HCl, at a pH of 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA) for 30
min on ice. Cell lysates were centrifuged at 13 000g for 30 min at 4 °C.
The concentration of the protein content was determined using Bio-
Rad protein assay solution. Equal amounts of cell lysate (40 μg) were
resolved by SDS-PAGE and transferred to polyvinylidene difluoride
(PVDF) membranes (PerkinElmer Life Sciences, Waltham, MA).
Membranes were blocked with 5% BSA/PBST for 2 h and incubated
with primary antibodies (rabbit polyclonal anti-HA antibody, Santa
Cruz cat#: sc-805, dilution 1:1000) overnight at 4 °C with shaking.
Following three washes with PBST (PBS containing Tween 20, 0.02%
v/v), membranes were incubated with the secondary antibody (IRDye
800CW Donkey anti-Rabbit, 1:10 000) for 1 h shaking at RT. Bound
antibodies were detected with LICOR.
Raji Cell Culture. In the washout experiment, Raji cell line derived
(20 000) cells were placed per well in a 96-well plate. The cells were
incubated with the Bfl-1 inhibitor 130G4 alone or in combination with
different concentrations of Fludarabine (F-ara-A) or etoposide for 48 h
at 37 °C in CO2 incubator. The in vitro cytotoxicity was measured in
all the samples after 48 h using PI/DiOC6 followed by flow cytometry
data analysis, and the data were reported as % SIA (specific induced
apoptosis, see below).
Chronic Lymphocytic Leukemia (CLL) Sampling and Cell Culture.
Peripheral blood mononuclear cells (PBMC) from patients with CLL
were obtained from the CLL Research Consortium tissue bank. After
CLL diagnosis was confirmed,55 patients provided written informed
consent for blood sample collection. The institutional review board of
the University of California, San Diego, approved the protocol.
PBMCs were isolated by Ficoll-Hypaque gradient density centrifuga-
tion (Cat# 17-1440-03, GE Healthcare Life Science) and used fresh or
viably frozen and stored in liquid nitrogen for later use.
PBMCs were separated from heparinized venous blood by density
gradient centrifugation using Ficoll-Hypaque media (GE Healthcare).
Samples with >95% double positive cells for CD5 and CD19, as
assessed by flow cytometry, were selected and used. Briefly, primary
CLL-B leukemia cells derived from CLL patients were cultured in
RPMI supplemented with 10% heat inactivated FBS (fetal bovine
serum, catalog # FB-02, Omega Scientific, Tarzana, CA) and 1%
antibiotic at a density of 3 × 105 cells per well in a total volume of 100
μL at 37 °C and 5% CO2. Primary CLL cells were cultured alone in
96-well round-bottom plates (catalog # 3596, Corning, NY) or
cocultured with NK-tert stromal cells in 96-well flat bottom plates
(catalog # 3799, Corning, NY) with a ratio of 20:1 (NK-tert/CLL) by
seeding 300 000 cells/well.56 The human mesenchymal NK-tert
stromal cell line was derived from bone marrow. Stroma-NK-tert
cells are fibroblast derived from human bone marrow and
immortalized with human telomerase reverse transcriptase (hTERT)
bearing exogene MFG-tsT-IRES-neo (RCB2350- RIKEN Bioresource
Center, Japan). These cells were obtained from the RIKEN Cell Bank
(RIKEN, Yokohama, Japan). NK-tert cells alone were maintained in
DMEM (catalog # 10-017-CV, Corning Cellgrov, Manassas, VA
20109) supplemented with 10% FBS and 1% antibiotic.
Flow Cytometry. The flow cytometric data collection and analysis
was carried out using FACScalibur (BD Biosciences, San Jose, CA)
and FlowJo software (version 9, TreeStar Inc., Ashland, OR).
Detection of Apoptosis. For assessment of apoptotic cells, first cells
alone or cocultured with stroma cell support were stained to select
CLL-B with CD19/CD5 antibodies to gate on CLL-B cells. The CLL-
B cell specific staining was done using a 1:40 dilution of CD19-PerCP-
Cy5.5 (catalog # 8045-0198, clone SJ25C1, eBioscience, San Diego)
and a 1:50 dilution of APC mouse antihuman CD5 (catalog # 555355,
clone UCHT2, BD Biosciences) specific antibodies. The staining was
done at 4 °C for 30 min followed by washing using FACS buffer two
times. Following that, apoptotic and viable cells were discriminated by
staining the cells with a 1:1000 dilution of 40uM 3,3′-dihexylox-
acarbocyanine iodide (DiOC6; catalog #D-273, Molecular Probes,
Eugene, OR, USA) for 30 min at 37 °C. Following DiOC6 staining,
samples were subjected to flow cytometry analysis.
Calculation of Specific Induced Apoptosis (SIA). In order to
discriminate the compound specific induced apoptosis vs background
spontaneous cell death from in vitro culture conditions, we calculated
the percentage of specific induced apoptosis (% SIA) using the
following formula: % SIA = [(compound induced apoptosis − media
only spontaneous apoptosis)/(100 − media only spontaneous
apoptosis)] × 100.
Statistical Analysis. The data sets were analyzed using GraphPad
Prism software (v. 5.0c; San Diego, CA). The statistical significance
was determined by using paired or unpaired Student’s t test or one-
way ANOVA followed by Bonferroni correction’s multiple compar-
isons test. Statistical differences for the mean values are indicated as
follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. The
IC50 value was defined as the drug concentration that inhibits 50% cell
growth compared with untreated controls and calculated by Graphpad
Prism 6.0 software. Unless indicated, data are presented as the mean ±
SEM.
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